Open Access 01-12-2018 | Research article
A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma
Published in: BMC Cancer | Issue 1/2018
Login to get access